Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
The risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer remains very small, but it is twice as high as previously reported, according to results of a new study led by researchers at the Johns Hopkins Kimmel Cancer Center.
Johns Hopkins researchers have developed a sugar-based molecular microcapsule that eliminates the toxicity of an anticancer agent developed a decade ago at Johns Hopkins, called 3-bromopyruvate, or 3BrPA, in studies of mice with implants of human pancreatic cancer tissue. The encapsulated drug packed a potent anticancer punch, stopping the progression of tumors in the mice, but without the usual toxic effects.
Researchers from Johns Hopkins have found that dense mats of interacting bacteria, called biofilms, were present in the majority of cancers and polyps, particularly those on the right side of the colon. The presence of these bacterial bunches, they say, may represent an increased risk for colon cancer and could form the basis of new diagnostic tests.
Johns Hopkins researchers report that their test of an interventional X-ray guidance device approved by the U.S. Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer.
After mining the genetic records of thousands of breast cancer patients, researchers from the Johns Hopkins Kimmel Cancer Center have identified a gene whose presence may explain why some breast cancers are resistant to tamoxifen, a widely used hormone treatment generally used after surgery, radiation and other chemotherapy.
Patients who receive chemotherapy and radiation after surgery for gastric cancer appear to have better survival rates than those who had surgery followed by only chemotherapy, according to results of a look-back study of more than 500 people by Johns Hopkins scientists.
When choosing a cancer surgeon, patients are more likely to prefer surgeons with specialized training and lots of experience far more than those who practice in a convenient location or were recommended by a friend, according to results of a new survey reported in the November issue of the Annals of Surgical Oncology.
A urine-based test for early detection and monitoring of bladder cancer and a plan to develop nanoparticles to deliver chemotherapy drugs to bladder tissue are among the first round of projects awarded research grants by the Johns Hopkins Greenberg Bladder Cancer Institute.
An evening of opera with special guest Marilyn Horne, iconic American opera singer, featuring performances by soprano Colleen Daly and tenor Rolando Sanz with direction and musical accompaniment by James Harp to benefit the Model Lyric Performing Arts Center and the Johns Hopkins Kimmel Cancer Center. A multi-course menu with wine pairing will be prepared by Pazo, a Baltimore Harbor East southern Italian restaurant. Valet parking is included.
The Centers for Disease Control and Prevention’s (CDC’s) Division of Cancer Prevention and Control (DCPC) has awarded the Johns Hopkins Kimmel Cancer Center’s Breast Cancer Program a $1.7 million grant over five years to fund educational programs, enhance support and increase awareness for young women diagnosed with breast cancer.
Five bladder cancer experts will be awarded research grants totaling $250,000 from the Johns Hopkins Greenberg Bladder Cancer Institute on Oct. 15. The grant awards will be the centerpiece of a day-long board meeting. The event will culminate with the unveiling of a ceremonial plaque marking the establishment of the new institute that was made possible with a landmark gift from Baltimore-area commercial real estate developer Erwin Greenberg and his wife, Stephanie Cooper Greenberg.
Johns Hopkins scientists have shown a strong association between tobacco use or exposure and infection with oral human papillomavirus type 16 (HPV16), the sexually transmitted virus responsible for mouth and throat cancers worldwide. The numbers of such cancers have increased 225 percent in the United States over the past two decades.
Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients’ need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response. Patients receive cyclophosphamide for two days after their bone marrow transplant, in addition to two other chemotherapy drugs given before the transplant.
In an analysis of genetic information among more than 87,000 men, a global team of scientists says it has found 23 new genetic variants — common differences in the genetic code — that increase a man’s risk for prostate cancer. The so-called meta-analysis, believed to be the largest of its kind, has revealed once hidden mutations among men in a broad array of ethnic groups comprising men of European, African, Japanese and Latino ancestry.
Prostate cancer patients whose tumors contain a shortened receptor called AR-V7 are less likely to respond to two widely used drugs for metastatic prostate cancer, according to results of a study led by researchers at Johns Hopkins’ Kimmel Cancer Center and Brady Urological Institute. If large-scale studies validate the findings, the investigators say men with detectable blood levels of AR-V7 should avoid these two drugs and instead take other medicines to treat their prostate cancer. A report on the work is described online Sept. 3 in the New England Journal of Medicine.
Breast cancer cells can lay the groundwork for their own spread throughout the body by coaxing cells within lymphatic vessels to send out tumor-welcoming signals, according to a new report by Johns Hopkins scientists.
A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report from Johns Hopkins Kimmel Cancer Center researchers.
A triple therapy for glioblastoma, including two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report by scientists at the Johns Hopkins Kimmel Cancer Center.
The Johns Hopkins Kimmel Cancer Center has been awarded three Telly Awards for two educational videos on pediatric and pancreatic cancers.
Physicians at Johns Hopkins have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the human papillomavirus (HPV) shed from cancer cells lingering in the mouth or other parts of the body. A description of the development is published in the July 31 issue of JAMA Otolaryngology – Head & Neck Surgery.
Cancer’s no game, but researchers at Johns Hopkins are borrowing ideas from evolutionary game theory to learn how cells cooperate within a tumor to gather energy. Their experiments, they say, could identify the ideal time to disrupt metastatic cancer cell cooperation and make a tumor more vulnerable to anti-cancer drugs.
Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and potentially making them vulnerable to immune-based therapies.
Cancer clinicians and a chaplain at the Johns Hopkins Kimmel Cancer Center have developed a new tool to help doctors, nurses and other health care providers talk to dying patients and families who are, literally, praying for a miracle.
A compound in saliva, along with common proteins in blood and muscle, may protect human cells from powerful toxins in tea, coffee and liquid smoke flavoring, according to results of a new study led by investigators at the Johns Hopkins Kimmel Cancer Center.
Baltimore-area commercial real estate developer Erwin L. Greenberg and his wife Stephanie Cooper Greenberg have pledged a $15 million gift to create the Johns Hopkins Greenberg Bladder Cancer Institute. Their gift is part of a $45 million co-investment with Johns Hopkins University, which will draw on the Johns Hopkins Kimmel Cancer Center’s multidisciplinary research teams, and will include faculty from the Johns Hopkins University School of Medicine’s Department of Radiation Oncology and Molecular Radiation Sciences, the Brady Urologic Institute, and the Departments of Pathology and Surgery.
Officials at the Johns Hopkins Kimmel Cancer Center today announced receipt of a $10 million gift from Under Armour Inc. to fund breast cancer, breast health support programs and a women’s wellness center.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins will use a $65 million gift toward the construction of a new patient care building that will be named for the late Albert P. “Skip” Viragh, Jr., a Maryland mutual fund investment leader and philanthropist. A pancreas cancer patient treated at Johns Hopkins, Mr. Viragh died of the disease in 2003 at age 62.
Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers from the Johns Hopkins Kimmel Cancer Center.
Johns Hopkins Kimmel Cancer Center investigators report they have designed a blood test that accurately detects the presence of advanced breast cancer and also holds promise for precisely monitoring response to cancer treatment.
In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies.
The following announcements are related to awards that have been presented during the American Association for Cancer Research (AACR) Annual Meeting 2014, held in San Diego April 5-9, to researchers at the Johns Hopkins Kimmel Cancer Center.
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.
In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy – delivered directly through a tumor’s blood supply – is working.
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.
Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study led by Johns Hopkins Kimmel Cancer Center investigators.
In a review article published Feb. 14 in The Lancet Oncology, Johns Hopkins experts identify three major sources of high cancer costs and argue that cancer doctors can likely reduce them without harm to patients. The cost-cutting proposals call for changes in routine clinical practice involved in end-of-life care, medical imaging and drug pricing.
Preliminary results of a small clinical trial show that a vaccine used to treat women with high-grade precancerous cervical lesions triggers an immune cell response within the damaged tissue itself. The Johns Hopkins scientists who conducted the trial said the finding is significant because measuring immune system responses directly in the lesions may be a more accurate way to evaluate so-called "therapeutic" vaccines than by the conventional means of blood analysis.
Investigators at Johns Hopkins report they have developed human induced-pluripotent stem cells (iPSCs) capable of repairing damaged retinal vascular tissue in mice. The stem cells, derived from human umbilical cord-blood and coaxed into an embryonic-like state, were grown without the conventional use of viruses, which can mutate genes and initiate cancers, according to the scientists. Their safer method of growing the cells has drawn increased support among scientists, they say, and paves the way for a stem cell bank of cord-blood derived iPSCs to advance regenerative medicine research.
In laboratory experiments conducted on human cell lines at the Johns Hopkins Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by a byproduct of alcohol, called acetaldehyde.
Allegheny Health Network and Johns Hopkins Medicine announced today that they have signed a memorandum of understanding (MOU) to seek to establish a formal affiliation between Allegheny and the Johns Hopkins Kimmel Cancer Center, a National Cancer Institute-designated comprehensive cancer center, for clinical collaborations, medical education, and a broad range of cancer research initiatives. Details of an initial five-year affiliation outlined in the MOU are expected to be finalized within the next few months, officials of the institutions say.
Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.
Scientists at the Johns Hopkins Kimmel Cancer Center will receive $90 million in new funding as part of a $540 million gift from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, to six U.S. institutions. The new award is among the largest for a single private gift to cancer research.
Johns Hopkins Kimmel Cancer Center investigators have genetically engineered a new mouse that mimics a common form of leukemia in humans. Studying the model could lead to new understanding of the disease, they say.